ESTRO 35 2016 _____________________________________________________________________________________________________ fusion. The treatment was designed with SmartArc with multiple arches made with Synergy. The dosage regimen used is Lagerwaard one: [RCT (20 Gy) + SIBmts (40 Gy)] / 5 frac. Positioning of the patient was checked daily with conebeam. Before starting the optimization we must be contoured 3mm ring around the calote we call follicles, and a contraction of the outer contour of 12mm we call volume CPE. We define two arcs (VMAT CCW 178 ° -60 ° and 300 ° -182 °), with the following objectives: follicles (DSEmax = 16 Gy, weight = 20; DSEmax = 5 Gy, weight = 1), brain-CPE (Dmax = 21Gy, weight = 100 and Dmin = 20 Gy, weight = 50), eyes (Dmax = 10 Gy, weight = 1). Later, we focus on separate metastases: optimization blocked prophylaxis (Optimization Type None) and create three structures: VI1 = PTV (MTS1) 5 mm VI2 = PTV (m2) 5 mm Epx = brain-VI1-VI2 . The objectives were PTVI (Dmax = 44Gy, despite Dmin = 100 and = 40 Gy weight = 50), Epx (Dmax = 30 Gy) and brainstem (Dmax = 23Gy), follicles (DSEmax = 16 Gy, weight = 20 ; DSEmax = 5 Gy, weight = 1) Verifying treatment was performed with the Compass software, and the Matrixx detector with gamma (4%, 1 mm) conditioning.
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Results: So far we have treated 15 patients, the differences in the images of fusion of less than 1 mm and the average correction IGRT of 1.24mm. No acute toxicity. Nor alopecia, or temporary removal,
Conclusion:
If we consider our VMAT optimization alopecia in WBRT + SIB with eXaFrame and eXaSkin, produce optimal aesthetic results. Among elderly patients, 38 (71.6%) were treated with RT alone, 9 patients (16.9%) with adjuvant TMZ, while 6 patients (11.3%) with a KPS ≥70 received hypoRT plus concurrent TMZ, followed by adjuvant chemotherapy in 3 (5.6%) of these cases. The median follow up time of the entire cohort was 13.6 months (range 1-47 months). A significant improvement in KPS from baseline to the end of radiation therapy was observed in 73 patients (76%). The median overall survival time was 6.7 months, reducing to only 2.5 months and 4 months respectively in elderly and younger patients with low performance status (KPS<70). The 6 months and 1 year survival rates were respectively 56.4% and 29.1%. In multivariate analysis, concomitant Temozolomide (HR:0.38, 95% CI 0.16-0.85,p=.020) and adjuvant TMZ (HR:0.28,95% CI 0.14-0.56,p=.000) emerged as significant indices of longer OS rates, while weaning from steroids (p=.18), extent of surgical resection (p=.17) and tumor site (p=.10) were not significant predictors of overall survival but showed a positive trend. Patients who received concomitant TMZ had a median survival time of 12.5 months compared with 6.3 months for those treated with RT alone (p=.017). Also the use of adjuvant chemotherapy resulted in improved survival compared to no sequential Temozolomide (10.8 vs 5.2 months, p=.001). In the elderly cohort, patients treated with adjuvant TMZ had median OS of 8.15 months as opposed to 6.4 months of those not receiving adjuvant chemotherapy (p=.001). A stronger impact of adjuvant TMZ has been reported in younger patients, with a median OS of 13.5 months in adjuvant TMZ group compared to 3.7 months (p=.001) in the other group. Moreover, younger patients receiving concurrent Temozolomide showed a significantly longer OS of 20 months compared to 5.1 months in patients not having TMZ (p=.006). Acute tolerance to radiotherapy was generally good. No grade 3-4 acute toxicity was observed.
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Conclusion:
Our findings seem to suggest that frail elderly patients with KPS at baseline < 70 do not benefit of an active treatment and could be carefully offered best supportive care. In the presence of a good functional status and a wide surgical resection, patients older than 65 years may take advantage of hypo-fractionated radiotherapy, followed by adjuvant TMZ. In younger patients with poor performance status, the significant survival gains obtained with combined modality treatment suggest that a maximum resection followed by combined radiation and chemotherapy should be recommended.
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